{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:35:37Z","timestamp":1774928137772,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T00:00:00Z","timestamp":1412208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T00:00:00Z","timestamp":1412208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1038\/jhh.2014.86","type":"journal-article","created":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T09:17:36Z","timestamp":1412241456000},"page":"316-323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry"],"prefix":"10.1038","volume":"29","author":[{"given":"S","family":"Friedrich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Zeymer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Dechend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Hagedorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Riemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Zemmrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Bramlage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Pittrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Senges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-5883","authenticated-orcid":false,"given":"R E","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,2]]},"reference":[{"key":"BFjhh201486_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507\u2013520.","journal-title":"JAMA"},{"key":"BFjhh201486_CR2","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281\u20131357.","journal-title":"J Hypertens"},{"key":"BFjhh201486_CR3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(98)08127-6","volume":"353","author":"F Gueyffier","year":"1999","unstructured":"Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 1999; 353: 793\u2013796.","journal-title":"Lancet"},{"key":"BFjhh201486_CR4","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R . Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903\u20131913.","journal-title":"Lancet"},{"key":"BFjhh201486_CR5","first-page":"1121","volume":"336","author":"F Turnbull","year":"2008","unstructured":"Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121\u20131123.","journal-title":"BMJ"},{"key":"BFjhh201486_CR6","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/HJH.0b013e32832aa6b5","volume":"27","author":"A Zanchetti","year":"2009","unstructured":"Zanchetti A, Grassi G, Mancia G . When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27: 923\u2013934.","journal-title":"J Hypertens"},{"key":"BFjhh201486_CR7","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","volume":"358","author":"NS Beckett","year":"2008","unstructured":"Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887\u20131898.","journal-title":"N Engl J Med"},{"key":"BFjhh201486_CR8","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1291\/hypres.31.2115","volume":"31","author":"JS Group","year":"2008","unstructured":"Group JS . Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008; 31: 2115\u20132127.","journal-title":"Hypertens Res"},{"key":"BFjhh201486_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/HYPERTENSIONAHA.109.146035","volume":"56","author":"T Ogihara","year":"2010","unstructured":"Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010; 56: 196\u2013202.","journal-title":"Hypertension"},{"key":"BFjhh201486_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr039","volume":"32","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Zhang X, Liu L, Zanchetti A, Group FS . Is a systolic blood pressure target <140\u2009mm\u2009Hg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J 2011; 32: 1500\u20131508.","journal-title":"Eur Heart J"},{"key":"BFjhh201486_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2125.2012.04375.x","volume":"75","author":"O Mukhtar","year":"2013","unstructured":"Mukhtar O, Jackson SH . Risk: benefit of treating high blood pressure in older adults. Br J Clin Pharmacol 2013; 75: 36\u201344.","journal-title":"Br J Clin Pharmacol"},{"key":"BFjhh201486_CR12","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","volume":"111","author":"AH Gradman","year":"2005","unstructured":"Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP . Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012\u20131018.","journal-title":"Circulation"},{"key":"BFjhh201486_CR13","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/j.1742-1241.2007.01473.x","volume":"61","author":"J Nussberger","year":"2007","unstructured":"Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007; 61: 1461\u20131468.","journal-title":"Int J Clin Pract"},{"key":"BFjhh201486_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1161\/01.HYP.0000253780.36691.4f","volume":"49","author":"E O'Brien","year":"2007","unstructured":"O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49: 276\u2013284.","journal-title":"Hypertension"},{"key":"BFjhh201486_CR15","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","volume":"49","author":"BH Oh","year":"2007","unstructured":"Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL . Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157\u20131163.","journal-title":"J Am Coll Cardiol"},{"key":"BFjhh201486_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","volume":"370","author":"S Oparil","year":"2007","unstructured":"Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221\u2013229.","journal-title":"Lancet"},{"key":"BFjhh201486_CR17","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/jhh.2009.107","volume":"24","author":"DA Duprez","year":"2010","unstructured":"Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN . Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens 2010; 24: 600\u2013608.","journal-title":"J Hum Hypertens"},{"key":"BFjhh201486_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1742-1241.2012.02893.x","volume":"66","author":"U Zeymer","year":"2012","unstructured":"Zeymer U, Dechend R, Deeg E, Kaiser E, Senges J, Pittrow D et al. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry. Int J Clin Pract 2012; 66: 251\u2013261.","journal-title":"Int J Clin Pract"},{"key":"BFjhh201486_CR19","unstructured":"Verband der forschenden Arzneimittelhersteller (VfA). Registry of non-interventional studies (NIS): 3A Register [accessed 11.03.2014]; Available from: http:\/\/www.vfa.de\/de\/arzneimittel-forschung\/datenbanken-zu-arzneimitteln\/nisdb\/nis-details\/_616."},{"key":"BFjhh201486_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(83)90977-7","volume":"2","author":"FH Messerli","year":"1983","unstructured":"Messerli FH, Sundgaard-Riise K, Ventura HO, Dunn FG, Glade LB, Frohlich ED . Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 1983; 2: 983\u2013986.","journal-title":"Lancet"},{"key":"BFjhh201486_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0735-1097(02)01923-X","volume":"40","author":"K Kario","year":"2002","unstructured":"Kario K, Eguchi K, Hoshide S, Hoshide Y, Umeda Y, Mitsuhashi T et al. U-curve relationship between orthostatic blood pressure change and silent cerebrovascular disease in elderly hypertensives: orthostatic hypertension as a new cardiovascular risk factor. J Am Coll Cardiol 2002; 40: 133\u2013141.","journal-title":"J Am Coll Cardiol"},{"key":"BFjhh201486_CR22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1152\/jappl.1985.59.4.1033","volume":"59","author":"JL Fleg","year":"1985","unstructured":"Fleg JL, Tzankoff SP, Lakatta EG . Age-related augmentation of plasma catecholamines during dynamic exercise in healthy males. J Appl Physiol (1985) 1985; 59: 1033\u20131039.","journal-title":"J Appl Physiol (1985)"},{"key":"BFjhh201486_CR23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1185\/03007990902785845","volume":"25","author":"TW Littlejohn 3rd","year":"2009","unstructured":"Littlejohn TW 3rd, Trenkwalder P, Hollanders G, Zhao Y, Liao W . Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009; 25: 951\u2013959.","journal-title":"Curr Med Res Opin"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/jhh201486.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201486","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201486.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T19:10:30Z","timestamp":1647544230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh201486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,2]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["BFjhh201486"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2014.86","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,2]]},"assertion":[{"value":"16 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FS, UZ, RD, IT, CZ, PB, DP, JS and RES have received speaker\u2019s fees and consulting honoraria from Novartis and other manufacturers of antihypertensive drugs. IH is a full-time employee of Novartis Pharma GmbH, Germany. TR reports no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}